RxDoctor Payments Data

Will Rutland, MD

Psychiatry · New Haven, CTNPI 1194256271

Payments from drug & device makers

$1,956in general payments, 2019–2025

Across 98 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$288
  • Neurocrine Biosciences, Inc.$229
  • AbbVie$196
  • Otsuka America Pharmaceutical, Inc.$179
  • Axsome Therapeutics, Inc.$175
  • Lundbeck LLC$172
  • plus $717 from 12 others

What the payments were for

  • Food & beverage$1,956100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,956 in reported general payments places this provider in the 80th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,022
Medicare patients
61
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$219,879
AustedoDeutetrabenazine18$72,620
TrintellixVortioxetine Hydrobromide33$16,064
Aripiprazole179$13,094
Quetiapine Fumarate206$2,910
Olanzapine OdtOlanzapine24$2,459
Buspirone Hcl109$1,990
Lamotrigine129$1,972
Bupropion XlBupropion Hcl111$1,942
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,828
Olanzapine48$1,495
Sertraline Hcl152$1,144
Escitalopram Oxalate113$1,083
Duloxetine Hcl46$1,011
Hydroxyzine Hcl67$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$229$219,87917 claims
Teva Pharmaceuticals USA, Inc.Austedo$30$72,62018 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$150$16,06433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →